Mesenchymal Stem Cell Therapy for Severe COVID-19 ARDS

Mesenchymal Stem Cell Therapy for Severe COVID-19 ARDS

Background: The COVID-19 pandemic reached Germany in spring 2020. No proven treatment for SARS-CoV-2 was available at that time, especially for severe COVID-19-induced ARDS. We determined whether the infusion of mesenchymal stromal cells (MSCs) would help to improve pulmonary function and overall ou...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of intensive care medicine 2021-06, Vol.36 (6), p.681-688
Hauptverfasser: Häberle, Helene, Magunia, Harry, Lang, Peter, Gloeckner, Henning, Körner, Andreas, Koeppen, Michael, Backchoul, Tamam, Malek, Nisar, Handgretinger, Rupert, Rosenberger, Peter, Mirakaj, Valbona
Format: Artikel
Sprache:eng
Schlagworte:
Adult
Aged
Cohort Studies
COVID-19 - complications
COVID-19 - mortality
COVID-19 - therapy
Critical Care
Female
Germany
Humans
Male
Mesenchymal Stem Cell Transplantation
Middle Aged
Original Research
Respiration, Artificial
Respiratory Distress Syndrome - mortality
Respiratory Distress Syndrome - therapy
Respiratory Distress Syndrome - virology
Survival Rate
Treatment Outcome
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background: The COVID-19 pandemic reached Germany in spring 2020. No proven treatment for SARS-CoV-2 was available at that time, especially for severe COVID-19-induced ARDS. We determined whether the infusion of mesenchymal stromal cells (MSCs) would help to improve pulmonary function and overall outcome in patients with severe COVID-19 ARDS. We offered MSC infusion as an extended indication to all critically ill COVID-19 patients with a Horovitz index
ISSN:0885-0666
1525-1489
DOI:10.1177/0885066621997365